Patients with dMMR endometrial cancer may benefit from immunotherapy1

Endometrial cancer has the highest rate of mismatch repair deficiency (dMMR) across tumor types2

  • 25%-30% of endometrial cancer patients have dMMR tumors3,4

dMMR endometrial cancer tumors can be associated with:

Icon: Recurrence rate

a higher
recurrence rate5

Icon: Distant recurrences

a higher rate of distant

Icon: Lynch syndrome

Lynch syndrome, a germline mutation that increases the risk
of other cancers6

Tumors with dMMR are more likely to respond to anti–PD-1 therapies like JEMPERLI7

  • Increased mutations promote antitumor immune cell reaction and increased tumor-infiltrating lymphocytes7

Test your endometrial cancer patients for dMMR6-9

Determine MMR status using immunohistochemistry (IHC)7-9

  • IHC is a reliable and accurate testing method to determine if a tumor is dMMR and identify patients who may benefit from immunotherapy7-9
  • There is an IHC-based, FDA-approved test that can confirm patient eligibility for JEMPERLI8,9

For recurrent/advanced endometrial cancer, National Comprehensive Cancer Network® (NCCN®) recommends dMMR testing if not previously done6

Testing for dMMR using IHC helps identify patients who may be appropriate for JEMPERLI7-9

Icon: Lightbulb
  • See the mechanism of action (MOA) for JEMPERLI

    The dMMR tumor cell journey 

    dMMR upregulates PD-1/PD-L110

    JEMPERLI is a PD-1–blocking antibody8

    • JEMPERLI binds to PD-1 to block interactions between PD-1 and PD-L1 or PD-L2
    • This releases the PD-1 pathway-mediated inhibition of the anti-tumor immune response to kill cancer cells*

    Blockade of the PD-1 receptor can restore T cell function11,12

    Inhibited T Cell

    *In mouse tumor models.8

    dMMR=mismatch repair deficient; PD-1=programmed death receptor-1; PD-L1=programmed death ligand 1; PD-L2=programmed death ligand 2.

    Inhibited T cell11,12

    • Cancer cells can increase expression of PD-L1 on their surface, which binds to PD-1 on T cells
    • This reduces the immune system's ability to identify and attack the cancer cells

    Activated T cell With JEMPERLI8,11,12

    • JEMPERLI binds to PD-1 receptors on the T cells, blocking PD-L1 or PD-L2 interactions
    • This enables T cells to identify and attack cancer cells by restoring cytotoxic activity in the T cell

    JEMPERLI harnesses the power of the immune system8

    Icon: Lightbulb

Recurrent/advanced endometrial cancer patients need additional effective and durable treatment options13-15

Most patients with recurrent or advanced endometrial cancer have a poor prognosis, with ORR dropping to <20% on 2L single-agent chemotherapy13,14*

Chart: ORR for 1L and 2L single-agent chemotherapy


Overall response rate (ORR) up to 27% has been reported in patients treated with paclitaxel who had exposure to 1 prior non-paclitaxel chemotherapy regimen.16

1L=first-line; 2L=second-line.

2L chemotherapy in patients with recurrent or advanced endometrial cancer, historically, has shown a median duration of response of less than 1 year (4.2 to 11 months)16,17

Median Duration of response less than one year
  • There is no generally accepted standard of care within the oncology community for the treatment of recurrent or advanced endometrial cancers that have progressed on or after platinum-based therapy14,15
  • Only 3 therapies or combinations of therapies for endometrial cancer have been approved by the FDA since 201718,19
Icon: JEMPERLI (dostarlimab-gxly) Response Rate

Learn about response with

Icon: JEMPERLI (dostarlimab-gxly) Trial

Explore the pivotal trial

Icon: JEMPERLI (dostarlimab-gxly) Mechanism of Action

Learn how JEMPERLI
activates T cells.